Analysis on the Current Situation， Causes and Countermeasures of the Supply Shortage of Pediatric Drug in China

Abstract

Abstract: In recent years， pediatric drug has attracted great attention in China. However， pediatric drug is facing supply shortage due to the low-level development， not meeting drug market demands. Based on the current situation of pediatric drug， the paper analyzes these problem from different perspectives， including the shortage quantity， variety， duration and area. Then according to the specific reasons， we put forward some countermeasures to guarantee the supply of pediatric drug.

Key words: font-size:medium, ">Pediatric drug； Drug shortage； Drug supply

CLC Number:

LI Yong, WEN Qing-hui, GUO Shu-jin, WANG Yi-yi, QIAN Jie. Analysis on the Current Situation， Causes and Countermeasures of the Supply Shortage of Pediatric Drug in China[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(2): 126-129.

References

[1]国家统计局. 中国儿童发展纲要（2011—2020年）》终期统计监测报告[EB/OL]. (2021-12-21) [2022-11-02]. http：//www.stats.gov.cn/xxgk/sjfb/zxfb2020/202112/t20211221_1825527.html
     [2]国家统计局.第七次全国人口普查主要数据情况[EB/OL]. (2021-05-11) [2022-11-02]. http：//www.stats.gov.cn/xxgk/sjfb/zxfb2020/202105/t20210511_1817195.html
     [3]中国卫生健康统计年鉴(2021) [M]. 北京：中国协和医科大学出版社，2021：126-128.
     [4]宁艳阳. 政策加持儿童药保障能力仍待提高[J]. 中国卫生，2022，(6)：92-93.
     [5]李曼，吴敏，倪明明，等. 儿科医联体中基层医疗机构的儿童药品短缺问题分析与改进措施[J]. 药学与临床研究， 2022， 30(02)：187-189.
     [6]王树月，贾玉芹，陈明珠，等. 2014—2019年国产儿童用药批准情况分析[J]. 中国药物评价，2021，38(2)：169-173.
     [7]李倩雯，叶乔峰，吕迁洲，等. 我国儿童药品目录与数据库相关问题分析及对策[J]. 中国药物评价，2021，38(3)：259-264.
     [8]倪明明，许静，王晓玲，等. 国内17家儿童医院药品短缺现状调研分析及建议[J]. 中国新药杂志，2020，29(17)：1957-1963.
     [9]中国卫生健康统计年鉴(2019) [M]. 北京：中国协和医科大学出版社，2019：126-127.
     [10]李赛赛，徐伟，杜雯雯，等.我国儿童基本药物的可获得性研究——基于全国19省份的调查分析[J]. 中国卫生政策研究， 2018， 11(12)：12-18.
     [11]魏国旭，王晓玲，李歆，等. 中国东部某省儿童基本药物可获得性、价格及可负担性调查分析[J]. 中国卫生政策研究，2019，12(10)：72-78.
     [12]洪峻，谭萌萌，王晓玲，等. 中国与日本儿童用药政策比较[J]. 中国药业，2022，31(13)：7-11.
     [13]国家医保局. 国家基本医疗保险、工伤保险和生育保险药品目录(2021年) [EB/OL]. (2021-12-03) [2022-10-20]. http：//www.nhsa.gov.cn/art/2021/12/3/art_14_7430.html
     [14]苏娜，田丽娟. 我国儿科药物临床试验数据分析及启示[J]. 中国新药杂志，2021，30(2)：150-153.
     [15]杜雯雯，徐伟，蔡功杰，等. 中国儿童用药可及性分析[J]. 中国现代应用药学，2018，35(1)：128-131.
     [16]安媛媛，阮艺宏，周辉，等. 我国药品采购制度的演变及当前带量采购制度的实施与完善[J]. 中国药事，2021，35(8)：847-855.
     [17]孙东旭，何贤英，崔芳芳，等. 基于医药电商平台的药品配送系统分析与设计[J]. 中国卫生事业管理 2021，38(4)：248-250，288.
     [18]Norman J， Madurawe RD， Moore CMV， et al. A New Chapter in Pharmaceutical Manufacturing： 3D-printed Drug Products[J]. Adv Drug Deliver Rev， 2017， 108：39-50.

Analysis on the Current Situation， Causes and Countermeasures of the Supply Shortage of Pediatric Drug in China

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	DAI Qi, LI Kang-xi, YE Qiao-bo, WEN Yong-sheng, XU Li, LI Ji. Reaserch Progress on Chemical Constituents，Pharmacological Effects and Toxicology of Bombyx Batryticatus [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 402-408.
[2]	ZHAO Lei, YANG Ming, WANG Hao, MA yu, MA Jin-gan, JIANG Da-cheng, WANG Lu-hong, ZAN Ke. Investigation and Risk Assessment of Mycotoxins in Seabuckthorn during Different Harvesting Periods and Drying Processes [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 377-383.
[3]	HONG Shu-hua, LIN Qi-shan, CHAI Jiang-hong, PAN Hong-ju. Study on the Determination of Zopiclone Related Substances and the Influence of Correction Factor [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 384-388.
[4]	LI Yue-chen, CUI Shao-jing, ZHAO Yue-ran. Determination of Aflatoxins in Huoxuezhitong Capsules by High Performance Liquid Chromatography Coupled with Post-column Photochemical Derivatization [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 390-395.
[5]	TIAN Jie, HAO Ai-yu, LU Lin, ZOU Pian, DONG Bin. Effect of Several Drug Compatibility on Sub-visible Particles in Infusions with Common Plastic Packagings [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 396-401.
[6]	YANG Yan-qing, CHEN Chun-mei, CHEN Wei, Wu Rui, WANG Xue-chang, DUAN Lian. Rapid Health Technology Evaluation of Sintilimab as First-line Treatment for Advanced Non-small Cell Lung Cancer [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 409-415.
[7]	JIANG Yi-Fan, CHEN Li-ping, ZHANG Ruo-yu, WU Pei-hao, QIU Jia-min, XUAN Jian-wei, BI Hui-chang. Construction of Clinical Comprehensive Value Evaluation System for Acid-inhibiting Drugs [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 416-421.
[8]	HUA Min-fan, SONG Cang-sang, LI Xing-de, LU Wei, MAO Pan-pan, WANG Guo-hui. Medication Adherence Forecast Model Research Progress in Clinical Application [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 422-425.
[9]	HUANG Bo, CAO Xiao-ming. Safety Analysis of Isotonic and Hypotonic Contrast Media for Coronary Angiography in Elderly Patients with Renal Impairment [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 426-429.
[10]	ZHANG Wen, YANG Wei-bing. Effects of Vitamin D Combined with Etocoxib on Rehabilitation，Bone Metabolism and Inflammation in Elderly Patients after Knee Replacement [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 430-434.
[11]	TIAN Jin-ya, DUAN Xiao-kai, FAN Shi-zhen. Effects of Budesonide combined with Ipratropium Bromide Solution on Lung Function， Blood Gas Analysis and Th1/Th2 Cytokines with Chronic Bronchitis [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 435-438.
[12]	ZHANG He-feng, LIANG Yu, LIU Ying, ZOU Ling-long, . Introduction of Bioanalytical Strategies and Methodologies for Genetically Modified Cell Therapy Products [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 369-376.
[13]	ZHANG He-feng, LIANG Yu, LIU Ying, ZOU Ling-long, . Bioanalysis of Gene Therapy Products： Method Development Strategy [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 361-368.
[14]	ZHANG Yu, LI Yu-man, XIA Xu-dong. Analysis of Suspected ADR Monitoring Data of Ginkgo Injection Preparations [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 439-444.
[15]	YAO Qing, LIU Ying, WANG Xiao-fang, GAO Ning, WANG Miao. Excel Calculates the Population Bioequivalence of Special Preparations [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(4): 332-337.